All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2021-06-28T11:24:54.000Z

What are the major advances for the triple-class exposed population?

By Becky Gribbell, Maria Kasimati, Zoe Brunn, Erika Roa
Featured
María-Victoria Mateos
Jun 28, 2021
Share:

Bookmark this article

During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Maria-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We asked, What are the major advances for the triple-class exposed population?

What are the major advances for the triple-class exposed population?

In this video, Mateos discusses the major advances in treatment for triple-class exposed patients with multiple myeloma, including melflufen, selinexor, and B-cell maturation antigen chimeric antigen receptor T-cell therapy.

 

More about...
Belantamab mafodotinCAR therapyEHAEHA 2021MelflufenRelapsed/refractory multiple myelomaSelinexorT-cell engagers

Your opinion matters

As a result of this content, I commit to reviewing the CARTITUDE clinical program to guide my understanding of cilta-cel in clinical practice.
28 votes - 5 days left ...

Related articles

Add bookmark

EHA2022 abstracts: What's hot in multiple myeloma?

To help navigate the exciting content being presented at the EHA2022 Congress, the Multiple Myeloma Hub Steering Committee members have provided their recommendations for the top abstracts to look...

Jun 6, 2022
Add bookmark

EHA2022 abstracts: What's hot in multiple myeloma?

To help navigate the exciting content being presented at the EHA2022 Congress, the Multiple Myeloma Hub Steering Committee members have provided...

Jun 6, 2022
Add bookmark

How do MM cells develop resistance to BCMA-targeted agents? Can it be overcome in the clinic?

During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Leo Rasche, University Hospital of Würzburg, Würzburg, DE. We asked, How do...

Jul 2, 2021
Add bookmark

How do MM cells develop resistance to BCMA-targeted agents? Can it be overcome in the clinic?

During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Leo Rasche, University Hospital...

Jul 2, 2021

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox